Chemotherapy for the treatment of non-small cell lung cancer can be quite toxic, however, durvalumab after chemotherapy can help manage toxicities while improving overall survival, according to the PACFIC trial.
Jamie E. Chaft, MD
Jamie Chaft, MD, specializes in medical oncology, with a special focus on lung cancer. She practices primarily in New York, NY, and is affiliated with Memorial Sloan Kettering Cancer Center.
Articles by Jamie E. Chaft, MD
Jamie E. Chaft, MD, discusses biomarkers used to identify patients with lung cancer who would benefit from immunotherapy and the possibility for future biomarkers in this setting.